Swiss drugmaker Roche said on Monday that a cocktail of its immunotherapy Tecentriq with chemotherapy boosted survival of patients with previously untreated extensive-stage small cell lung cancer compared with chemotherapy alone.
"These are the first positive Phase III survival results for any immunotherapy-based combination in the initial treatment of extensive-stage small cell lung cancer," Roche said in a statement. (Reporting by John Miller; Editing by Michael Shields)